e-learning
resources
Paris 2018
Tuesday, 18.09.2018
CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prognostic factors in Korean patients with chronic hypersensitivity pneumonitis
Y. Kim (Seoul, Republic of Korea), J. Choe (Seoul, Republic of Korea), E. Chae (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea), D. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea)
Source:
International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Session:
CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Session type:
Poster Discussion
Number:
3663
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Kim (Seoul, Republic of Korea), J. Choe (Seoul, Republic of Korea), E. Chae (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea), D. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea). Prognostic factors in Korean patients with chronic hypersensitivity pneumonitis. 3663
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
HISTOLOGICAL FINDINGS IN TRANSBRONCHIAL CRYOBIOPSIES OBTAINED FROM PATIENTS AFTER COVID-19
The impact of anti-IgE treatment on the airway microbiome in asthma.
Does “UIPAF” really exist?
Related content which might interest you:
Prognostic factors in chronic hypersensitivity pneumonitis
Source: Eur Respir Rev, 29 (156) 190167; 10.1183/16000617.0167-2019
Year: 2020
Prognostic characteristics in chronic hypersensitivity pneumonitis.
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Criteria for PF-ILD in a cohort of patients with chronic hypersensitivity pneumonitis
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Prognostic factors in severe eosinophilic asthma in children
Source: International Congress 2018 – The bad and the ugly in paediatric asthma: comorbidities and exacerbations
Year: 2018
Impact Prognostic impact of comorbidities in patients with chronic Hypersensitivity Pneumonitis
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018
Prognostic factors in severe eosinophilic asthma
Source: International Congress 2018 – Biomarkers and lung function in airway disease
Year: 2018
Acute exacerbation in patients with bronchiectasis: What prognostic factors?
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Fibrosis score predicts mortality in patients with chronic hypersensitivity pneumonitis
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Prevalance and outcomes of pulmonary hypertension in chronic hypersensitivity pneumonitis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
Mortality risk prediction with ILD-GAP index in a portuguese chronic hypersensitivity pneumonitis cohort
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Mechanisms of exercise limitation in patients with chronic hypersensitivity pneumonitis
Source: ERJ Open Res, 4 (3) 00043-2018; 10.1183/23120541.00043-2018
Year: 2018
Predictive factors of bronchiectasis acute exacerbation severity
Source: Virtual Congress 2021 – Bronchiectasis
Year: 2021
Factors associated with increased arterial stiffness in patients with chronic hypersensitivity pneumonitis
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
Clinical features and predictive factors for acute exacerbation of idiopathic pulmonary fibrosis
Source: Annual Congress 2007 - Clinical aspects of idiopathic pulmonary fibrosis
Year: 2007
Factors predicting response to azathioprine in chronic hypersensitivity pneumonitis – the importance of BAL lymphocytosis
Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Year: 2018
Mortality and survival predictor in chronic hypersensitivity pneumonitis
Source: International Congress 2016 – Sarcoidosis
Year: 2016
Squeaks in hypersensitivity pneumonitis: prevalence and clinical correlates
Source: International Congress 2019 – Pathogenesis and prognosis of interstitial lung disease of known origin
Year: 2019
Prognostic factors affecting survival of idiopathic pulmonary fibrosis in Korean population
Source: Eur Respir J 2007; 30: Suppl. 51, 578s
Year: 2007
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Source: Eur Respir J 2011; 37: 356
Year: 2011
Chronic hypersensitivity pneumonitis with familial history of interstitial lung disease
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept